GlassScriptPhysician profile
Odiel Jean-Baptiste
NPI 1881938819
$10,764.90
in general payments reported to CMS, 2019-2025
29 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $627 · 2021: $1,076 · 2022: $1,484 · 2023: $1,846 · 2024: $2,131 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,205 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,205.41 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,772.89 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $2,969.74 | 2019-2025 | Biktarvy |
| Janssen Biotech, INC. | $905.78 | 2019-2023 | Symtuza |
| Janssen Products, LP | $549.43 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $516.06 | 2022-2025 | Trogarzo, Egrifta |
| Merck Sharp & Dohme LLC | $391.42 | 2019-2025 | Pifeltro, Delstrigo |
| Abbvie INC. | $274.02 | 2019-2024 | |
| Indivior INC. | $266.50 | 2023-2025 | Sublocade, Perseris |
| Emd Serono, INC. | $210.56 | 2019-2025 | Serostim |
| Napo Pharmaceuticals INC | $141.50 | 2019-2024 | Mytesi |
| Amgen INC. | $106.88 | 2023-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $89.33 | 2024-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $81.49 | 2020-2025 | Airsupra, Farxiga |
| Neurocrine Biosciences, INC. | $59.81 | 2024-2025 | Ingrezza |
| Orexo US, INC. | $58.69 | 2022-2023 | Zubsolv |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $50.59 | 2025 | Brixadi |
| Astellas Pharma US INC | $50.44 | 2024 | Veozah |
| Almatica Pharma LLC | $34.60 | 2022 | |
| Smith+Nephew, INC. | $32.45 | 2019 | |
| Glaxosmithkline, LLC. | $29.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.42 | 2023 | Glyxambi, Synjardy, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.02 | 2025 | Caplyta |
| Evoke Pharma, INC. | $21.78 | 2020 | |
| Sunovion Pharmaceuticals INC. | $18.81 | 2022 | |
| Shield Therapeutics INC | $15.66 | 2022 | |
| Exact Sciences Corporation | $15.10 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $14.36 | 2023 | Gvoke Hypopen |
| Alkermes, INC. | $14.22 | 2025 | Vivitrol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Odiel Jean-Baptiste listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.